Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Management of Rectal Cancer Jacques Heppell, MD Mayo Clinic Scottsdale, Arizona JH012804 JH012804 RECTAL CANCER • 42,000 patients are diagnosed each year in the US • 8,500 patients die of this disease JH012804 JH012804 JH012804 The Prevention of Invasive Cancer of the Rectum • ‘ • The results of the 25+ year Cancer Detection Center study, including 20,000 participants and 100,000+ patient-years experience, demonstrate the obviation of appearance of most lower bowel cancers associated with a program of annual proctosigmoidoscopy and adenomatous polyp removal. • Cancer 41:1137-1139,1978 . JH012804 Screening JH012804 Incidence per 100,000 JH012804 AJCC STGE OF COLORECTAL NEOPLASMS: ARIZONA, ALL AGES JH012804 Japanese Scientists train Dogs to detect Colorectal Cancer ( Gut, 2011) JH012804 JH012804 JH012804 Who should take care of patients with rectal cancer? JH012804 Designated Center of Excellence ! • SUCCESSFUL IMPLEMENTATION OF A COMMUNITIES OF PRACTICE (COP) MODEL TO FACILITATE QUALITY IMPROVEMENT INITIATIVES IN COLORECTAL CANCER SURGERY • LJ Williams et al. Department of Surgery and Regional Cancer Program, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Can JH012804 Team Approach • Expert surgeon (TME,autonomic nerve and sphincter preservation) • Medical oncologist • Radiation oncologist • Nursing • Nutritionist • Psychologist JH012804 SURGERY FOR RECTAL CANCER Goals • Cure • Local control • Sphincter preservation • Preservation of sexual and urinary function JH012804 TECHNIQUE: “ Old Style” • Blunt dissection commonly used • 30% local failure (worldwide) • 60% distant metastasis • High rates of impotence and urinary dysfunction JH012804 PRIMARY GOAL OF SURGERY • Complete excision of all mesorectal disease, enveloped within intact visceral layer of pelvic fascia, together with negative lateral or circumferential margin JH012804 TOTAL MESORECTAL EXCISION JH012804 TME ALONE "High Risk Patients" T3, N0, M0 or any T, N1-2, M0 Local recurrence 5-8% Distant metastasis 25% JH012804 Norwegian Rectal Cancer Group • 29% local recurrence rate among 250 surgeons performing 1-14 resections for rectal cancer in 2 years • Establishment of a system for preceptorships to teach TME on a national level and Pathologists trained to evaluate quality of the specimens • Voluntary reduction of the number of surgeons operating on rectal carcinoma (250 to 50) JH012804 Norwegian Rectal Cancer Group • • • • TME performed In 1994 : 78% of cases In 1998: 98% of cases Local recurrence rate reduced to 8 %! JH012804 NIH Consensus on Adjuvant Therapy for Patients with Rectal Cancer 1990 JH012804 WAS THE NIH CONSENSUS RIGHT? • Quality of life • Bowel function • Most important treatment variable (the surgeon) JH012804 Chemoradiation: The Functional Cost JH012804 SUMMARY OF BOWEL FUNCTION IN THE 2 GROUPS Non-Radiation (59 Patients) No. of bowel movements/day Medican (range) 4 Clustering 5 Awoken at night for movement Incontinence None Occasional Frequent Wear a pad Perianal skin irritation Regularly use Lomotil ± Imodium Unable to differentiate stool from gas Liquid consistency (sometimes or always) Unable to defer defecation >15 min Need to defecate again within 30 min Bowel function different to preoperative 2 (1-7) 83% 3% 14% 14% – 93% 7% 0% 10% 12% 5% 15% 5% 19% 37% 61% Chemoradiotherapy (41 Patients) 7 (1-20) 22% 42% 37% 46% – 44% 39% 17% 41% 41% 58% 39% 29% 78% 88% 93% p Value <0.001 – – – <0.001 <0.001 – – – <0.001 <0.001 <0.001 0.009 0.001 <0.001 <0.001 JH012804 0.001 JH012804 R.J. Nicholls Br J Surg,1996 Apart from the occasional tumor, which is suitable for local excision, most low rectal cancers are best treated by anterior resection with complete removal of the rectum; the construction of the coloanal reservoir should allow routine sphincter saving. This surgery may be carried out independently of adjuvant radiotherapy by which, if given, should be administered before operation JH012804 Pre-op vs Post-op Chemoradiation • Sauer R. et al. NEJM 2004 • Randomized 421 patients pre-op and 402 patients post-op • 5 year survival 76% vs 74% (p=0.8) • Toxicity: 27 % vs 40% ( p=0.001) • Local control • Increased sphincter saving rate JH012804 DOWNSTAGING • Reduce volume of primary tumor • Decrease rectal wall invasion • Sterilize metastatic lymph nodes JH012804 JH012804 JH012804 RECTAL CANCER Locally Advanced Unresectable • Addition of chemotherapy to preoperative radiation therapy increases down-staging and resectability rates for fixed and tethered lesions JH012804 PREOPERATIVE CHEMOTHERAPY Theoretical Benefits • No delay in starting systemic therapy • Toxicity rates may be lower • Radiosensitizing effect of 5-FU • Downstaging may allow sphincter-saving procedure JH012804 JH012804 IORT JH012804 First report of APR technique at Mayo JH012804 Dr. Claude F. Dixon 1939 First anterior resection JH012804 JH012804 Rectosigmoid 15 cm Upper third 11 cm Middle third 7 cm Lower third Anal canal JH012804 Knight and Griffen, 1980 Roticulator A B C D E JH012804 • SURGERY: Apples and oranges: the low and mid versus the upper rectum • Martin Weiser & Leonard Saltz JH012804 JH012804 JH012804 COLONIC-POUCH ANAL ANASTOMOSIS Rolland Parc • 341 cases • 1984-97 • 28% of all rectal cancer • Improved function • 20% emptying difficulty JH012804 JH012804 JH012804 JH012804 JH012804 Splenic vein Inferior mesenteric vein Duodenum Inferior mesenteric artery JH012804 JH012804 JH012804 JH012804 Hand assisted vs Laparoscopic assisted • Larson DW et al Tech Coloproctol 2010 • Same oncologic results at 3 years but length of stay, time to soft diet, incision length, pain score better with laparoscopic assisted JH012804 ACOSOG Z6051 JH012804 JH012804 Endo anal vs Stapled anastomosis • Better function with stapler but preferable to do endo- anal anastomosis : • Intersphincteric dissection • Very narrow pelvis • Enlarged prostate • Prior radiation for prostate cancer • Short margin ! JH012804 Colo-anal anastomosis anastomosis JH012804 Indications for APR • • • • Inadequate sphincter : low Hartmann? Sphincter invasion Inadequate margin Patient wishes ! JH012804 MRI or Endorectal US • Better selection of high-risk lesions amenable to downstaging by preoperative chemo-radiation while reserving early-stage disease for surgery alone JH012804 JH012804 Isolated Adrenal Metastase JH012804 RECTAL CANCER Selective Approach Based on Preop Imaging • Rectal endosonography – T1, local excison – T2T3 radical surgery JH012804 JH012804 LOCAL EXCISION • Careful selection (5%) • Endorectal ultrasound essential in assessing penetration of rectal wall • Accessible, small, confined to rectal wall and without anaplastic histology JH012804 JH012804 JH012804 Local treatment failure • “Low salvage rates after radical surgery argue for aggressive additional therapy for patients whose initial tumors showed invasion of muscularis propria (T2), positive margins, poor differentiation,or lymphovascular invasion” JH012804 LOCAL EXCISION • Deep • Dark • Difficult JH012804 Trans anal Endoscopic Microsurgery JH012804 JH012804 JH012804 PREOPERATIVE CHEMO-RADIATION Creighton Univ MSK Duke University MD Anderson NW University No. Complete Pathologic Response, % 20 32 43 77 30 35 9 27 29 20 JH012804 RESPONDERS TO NEOADJUVANT THERAPY • 644 patients with proctectomy after neoadj Rx retrospectively (TE Read) • ypT0 = 2% positive nodes • ypT1 = 4% “ • ypT2 = 23% “ • ypT3 = 47% “ • ypT4 = 48% “ JH012804 “This study has very significant implications. It suggests that patients who respond well to preoperative chemoradiation may be safely treated by local excision and spared the morbidity of radical surgery.” Neil H. Hyman, MD JH012804 ACOSOG Z6041 • Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) of uT2uN0 rectal cancer (RC) treated by local excision (LE): Results of the ACOSOG Z6041 trial JH012804 What do you do ? • Radical Surgery • Wide local excision • Wait and see ? JH012804 JH012804 JH012804 JH012804 Future research • Robotics > my eye! JH012804 Ernestine Hambrick JH012804 JH012804